Dana A, Baxter G F, Walker J M, Yellon D M
Hatter Institute for Cardiovascular Studies, Department of Academic and Clinical Cardiology, University of College Hospital and Medical School, London, England, United Kingdom.
J Am Coll Cardiol. 1998 Apr;31(5):1142-9. doi: 10.1016/s0735-1097(98)00054-0.
This study was designed to examine whether the myocardium can be maintained in a protected state by extending the delayed phase of cardioprotection with chronic, intermittent adenosine A1 receptor activation.
Several recent studies have explored the temporal characteristics of the protective effects of ischemic preconditioning. Two distinct phases of myocardial protection have been described: the short-lived immediate phase, or "classic" preconditioning, and the delayed phase, or "second window of protection" (SWOP). Previous studies have examined the potential for extending the duration of classic preconditioning by repeated application of the preconditioning stimulus. Pretreatment with either multiple episodes of ischemia or continuous infusion of a selective adenosine A1 receptor agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), resulted in attenuation of the protective effects of preconditioning, implying downregulation of the receptors involved in triggering classic preconditioning.
Male New Zealand White rabbits were treated with repeated intravenous boluses of CCPA, 100 microg/kg body weight, or 0.9% saline at 48-h intervals. Forty-eight hours after the fifth dose (day 10), the animals were anesthetized and subjected to 30 min of coronary occlusion, followed by 120 min of reperfusion. Infarct size was determined as a percentage of myocardial risk volume using tetrazolium staining. To further explore whether the rabbits had developed tolerance to the effects of adenosine A1 receptor activation, a subgroup of animals were treated with a further bolus of CCPA, 100 microg/kg, at the end of the reperfusion period, and the hemodynamic response was monitored for 10 min before excision of the heart.
Pretreatment with intermittent doses of CCPA resulted in a 42% reduction in the infarct to risk ratio compared with vehicle pretreatment (26.6+/-3.7% vs. 45.9+/-5.5%, p < 0.01). Furthermore, CCPA treatment at the end of reperfusion resulted in identical hypotension and bradycardia in both groups.
We conclude that rabbits can be maintained in a protected state against myocardial infarction by repeated activation of adenosine A1 receptors, with no evidence of tachyphylaxis to the infarct-limiting or hemodynamic effects of CCPA. This finding suggests that adenosine A1 receptor activation may hold promise as a new approach to long-term cardioprotection.
本研究旨在探讨通过慢性间歇性激活腺苷A1受体来延长心脏保护的延迟期,是否能够使心肌维持在受保护状态。
最近的几项研究探讨了缺血预处理保护作用的时间特征。心肌保护存在两个不同阶段:短暂的即刻期,即“经典”预处理;以及延迟期,即“第二保护窗”(SWOP)。以往研究考察了通过重复施加预处理刺激来延长经典预处理持续时间的可能性。多次缺血预处理或持续输注选择性腺苷A1受体激动剂2-氯-N6-环戊基腺苷(CCPA)进行预处理,均导致预处理保护作用减弱,这意味着参与触发经典预处理的受体下调。
雄性新西兰白兔每隔48小时静脉推注100μg/kg体重CCPA或0.9%生理盐水。在第五次给药后48小时(第10天),将动物麻醉,进行30分钟冠状动脉闭塞,随后再灌注120分钟。使用四氮唑染色法将梗死面积确定为心肌危险体积的百分比。为进一步探究兔子是否对腺苷A1受体激活的作用产生耐受,在再灌注期结束时,对一组动物再推注100μg/kg CCPA,并在心脏切除前监测10分钟血流动力学反应。
与载体预处理相比,间歇性给予CCPA预处理使梗死与危险比降低了42%(26.6±3.7%对45.9±5.5%,p<0.01)。此外,再灌注结束时给予CCPA治疗,两组均出现相同程度的低血压和心动过缓。
我们得出结论,通过重复激活腺苷A1受体可使兔子维持在抗心肌梗死的保护状态,且没有证据表明对CCPA的梗死限制或血流动力学作用产生快速耐受。这一发现表明,腺苷A1受体激活可能有望成为一种长期心脏保护的新方法。